New epigenetic drug against Mantle Cell Lymphoma

Jun 13, 2018, Drug Target Review (UK)
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL)…

https://www.drugtargetreview.com/news/32438/epigenetic-drug-mantle-cell-lymphoma/

QUIMATRYX DEVELOPS AN EFFECTIVE EPIGENETIC DRUG AGAINST MANTLE CELL LYMPHOMA

QUIMATRYX has developed an epigenetic drug that has shown great efficacy in animal models against Mantle Cell Lymphoma.

https://lymphomanewstoday.com/2018/06/21/qtx125-slows-mantle-cell-lymphoma-progression-mouse-study/

Researchers Develop New Epigenetic Drug Against Mantle Cell Lymphoma

Jun 12, 2018, Pharmaceutical Processing

https://www.rdmag.com/news/2018/06/researchers-develop-new-epigenetic-drug-against-mantle-cell-lymphoma

Investor search in Quimatryx

Quimatryx has hired NORGESTION to search for one or more partners to rise €3 Million in two planned financial rounds between 2018 and 2019. This amount will be used to develop Quimatryx compound QTX125 (selective inhibitor against HDAC6) to clinical phase I for mantle cell lymphoma.